4.5 Interaction with other medicinal products and other forms of interaction 
 Delstrigo  is a complete regimen f or the treatment of HIV
-
1 inf ection; theref ore, Delstrigo  should notbe administered with other antiretroviral medicinal products
. Inf ormation regarding potentialmedicinal product interactions with other antiretroviral medicinal products  is not provided.Interaction studies have only been perf ormed in adults.Delstrigo  contains doravirine
, lamivudine, and tenof ovir disoproxil
, theref ore any interactionsidentif ied for these
 individually are relevant to Delstrigo  and are presented in Table
 1.Ef fects of  other medicinal products on doravirine, lamivudine
, and tenof ovir  disoproxil 
 Doravirine 
 Doravirine is primarily metaboli sed by CYP3A, and medicinal products that induce or inhibit CYP3Aare expected to
 af f ect the clearance of  doravirine
 (see section  5.2). Doravirine/lamivudine/tenofovirdisoproxil should not be co
-administered with medicinal products that are strong CYP3A enzymeinducers as signif icant decreases in doravirine plasma concentrations are expected to occur, whichmay decrease the ef f ectiveness of  doravirine/lamivudine/tenof ovir disoproxil
 (see sections
 4.3and 5.2).Co-administration with the moderate CYP3A inducer rif abutin decreased doravirine concentrations(see Table  1). When Delstrigo  is co -administered with rif abutin, a 
100 mg dose of doravirine shouldbe given  daily, approximately
 12 hours af ter doravirine/ lamivudine/tenof ovir disoproxil dose (seesection  4.2).Co-administration of
 doravirine/lamivudine/tenof ovir disoproxil with other moderate CYP3A inducershas not been evaluated
, but decreased doravirine concentrations are expected.  If  co-administrationwith other moderate CYP3A inducers (e.g., debraf enib, lesinurad, bosentan, thioridazine, naf cillin,modaf inil, telotristat ethyl)
 cannot be avoided, a 
100 mg dose of  doravirine should be administereddaily, approximately
 12 hours  af ter the administration of doravirine/lamivudine/tenof ovir disoproxildose (see section  4.2).Co-administration of  doravirine/lamivudine/tenofovir disproxil
 and medicinal products
 that areinhibitors of CYP3A may result in increased plasma concentrations of  doravirine. However, no doseadjustment is needed when doravirine is co
-administered with CYP3A inhibitors.Lamivudine 
 Because lamivudine is primarily eliminated by the kidneys through a combination of glomerularf iltration and active tubular secretion (see section
 5.2), co -administration ofdoravirine/ lamivudine/ tenof ovir disoproxil  with medicinal products
 that reduce renal f unction orcompete for active tubular secretion may increase serum concentrations of  lamivudine .Tenofovir disoproxil 
 Because tenof ovir is primarily eliminated by the kidneys through a combination of  glomerularf iltration and active tubular secretion (see section
 5.2), co -administration ofdoravirine/lamivudine/tenof ovir disoproxil
 with medicinal products that reduce renal f unction orcompete for active tubular secretion via OAT1, OAT3 or MRP4 may increase serum concentrations oftenof o vir.7Due to the tenof ovir disoproxil component of  doravirine/ lamivudine/tenof ovir disoproxil , use of  theproduct  should be avoided with concurrent or recent use of  nephrotoxic medicinal products. Someexamples include,  but are not limited to, acyclovir
, cidof ovir, ganciclovir, valacyclovir, valganciclovir,aminoglycosides (e.g., gentamicin), and high
-dose or multiple NSAIDs ( see section  4.4).Ef fects of  doravirine, lamivudine
, and tenof ovir  disoproxil  on other medicinal products 
 Doravirine 
 Doravirine at a dose of 100
 mg once daily is not likely to have a clinically relevant eff ect on theplasma concentrations of  medicinal products that are dependent on transport proteins f or absorptionand/or elimination or that are metaboli sed by CYP enzymes.However, co
-administration of  doravirine and the sensitive CYP3A substrate midazolam resulted in a
18 
% decrease in midazolam exposure, suggesting that doravirine may be a weak CYP3A inducer.Theref ore, caution should be used when co
-administering doravirine with medicinal products
 that aresensitive CYP3A substrates that also have a narrow therapeutic window (e.g., tacro limus andsirolimus).Lamivudine 
 Lamivudine does not inhibit or induce CYP enzymes.Tenofovir 
 Based on the results of  in vitro  experiments and the known elimination pathway of  tenof ovir, thepotential f or CYP
-mediated interactions involving tenof ovir with other medicinal products is low.Interaction  table 
 Table 1  shows the established and other potential medicinal product interactions with the individualcomponents of  Delstrigo  but is not  all inclusive  (increase is indicated as ↑, decrease is indicated as ,and no change as 
). For potential medicinal product interactions with tenof ovir disoproxil orlamivu dine, (see section s 4.4 and  5.2).Table 1 : Interactions between the individual components of Delstrigo  and other medicinalproducts 
 Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxil 
 Acid -reducing agentsantacid ( aluminium  andmagnesium hydroxide oralsuspension)(20 m 
 L SD,doravirine 100
 mg SD)  doravirine 
 AUC 1.01 (0.92, 1.11)Cmax 
0.86 (0.74, 1.01)C24 
1.03 (0.94, 1.12)No dose adjustment is required.pantoprazole(40 mg QD,doravirine  100 mg SD) doravirine 
 AUC 0.83 (0.76, 0.91)Cmax 
0.88 (0.76, 1.01)C24 
0.84 (0.77, 0.92)No dose adjustment is required.omeprazole  Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
  doravirine 
 No dose adjustment is required.8Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxil 
 Angiotensin converting enzyme inhibitorslisinopril 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil .Expected:
  lisinopril 
 No dose adjustment is required.Antiandrogensenzalutamide 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
 doravirine(Induction of  CYP3A)Co-administration iscontraindicated
.Antibioticsnaf cillin 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected: 
↓ doravirine(Induction of  CYP3A)Co-administration should beavoided. If  co -administrationcannot be avoided, a 100
 mg doseof  doravirine should be takendaily, approximately
12 h af ter thedose ofdoravirine/ lamivudine/ tenof ovirdisoproxil .Anticonvulsantscarbamazepineoxcarbazepinephenobarbitalphenytoin 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
 doravirine(Induction of  CYP3A)Co-administration iscontraindicated.Antidiabeticsmetf ormin(1 000 mg SD,doravirine 100
 mg QD)  metf ormin 
 AUC 0.94 (0.88, 1.00)Cmax 
0.94 (0.86, 1.03)No dose adjustment is required.canaglif lozinliraglutidesitagliptin 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected: 
  canaglif lozin
  liraglutide
  sitagliptin 
 No dose adjustment is required.9Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxil 
 Antidiarrh oealstelotristat ethyl 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
↓ doravirine(Induction of  CYP3A)Co-administration should beavoided. If  co -administrationcannot be avoided, a 100
 mg doseof  doravirine should be takendaily, 12 h af ter the  dose ofdoravirine/ lamivudine/ tenof ovirdisoproxil .Antigout and uricosuric agentslesinurad 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected: 
↓ doravirine(Induction of  CYP3A)Co-administration should beavoided. If  co -administrationcannot be avoided, a 100
 mg doseof  doravirine should be takendaily, approximately 
12 h af ter thedose ofdoravirine/ lamivudine/ tenof ovirdisoproxil .Antimycobacterials 
 Single dose rif ampicin(600 mg SD, doravirine 100
 mg SD)Multiple dose rif ampicin(600 mg QD, doravirine  100 mg SD)  doravirine 
 AUC 0.91 (0.78, 1.06)Cmax 
1.40 (1.21, 1.63)C24 
0.90 (0.80, 1.01)
 doravirine 
 AUC 0.12 (0.10, 0.15)Cmax 
0.43 (0.35, 0.52)C24 
0.03 (0.02, 0.04)(Induction of  CYP3A)Co-administration iscontraindicated.rif apentine 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
 doravirine(Induction of  CYP3A)Co-administration iscontraindicated.rif abutin(300 mg QD, doravirine  100 mg SD) doravirine 
 AUC 0.50 (0.45, 0.55)Cmax 
0.99 (0.85, 1.15)C24 
0.32 (0.28, 0.35)
 (Induction of  CYP3A)
 If  doravirine/ lamivudine/tenof ovir disoproxil  is co -administered with rif abutin, a
100 mg dose of  doravirine shouldbe taken daily, approximately 12
 hafter dose ofdoravirine/ lamivudine/ tenof ovirdisoproxil .10Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxil 
 Antineoplasticsmitotane 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
 doravirine(Induction of  CYP3A)Co-administration iscontraindicated.Antipsychoticsthioridazine 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected: 
↓ doravirine(Induction of  CYP3A)Co-administration should beavoided. If  co -administrationcannot be avoided, a 100
 mg doseof  doravirine should be takendaily, approximately 12 h af ter thedose ofdoravirine/ lamivudine/ tenof ovirdisoproxil .Azole antif ungal agentsketoconazole(400 mg QD, doravirine  100 mg SD) doravirine 
 AUC 3.06 (2.85, 3.29)Cmax 
1.25 (1.05, 1.49)C24 
2.75 (2.54, 2.98)(Inhibition of  CYP3A)No dose adjustment is required.f luconazoleitraconazoleposaconazolevoriconazole 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
 doravirine(Inhibition of  CYP3A)No dose adjustment is required.Calcium channel blockersdiltiazemverapamil 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
 doravirine(Inhibition of  CYP3A)No dose adjustment is required.11Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxil 
 Cystic fibrosis treatmentlumacaf tor 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
 doravirine(Induction of  CYP3A)Co-administration iscontraindicated
.Endothelin receptor antagonistsbosentan 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
↓ doravirine(Induction of  CYP3A)Co-administration should beavoided. If  co -administrationcannot be avoided, a 100
 mg doseof  doravirine should be takendaily, approximately
12 h af ter thedose ofdoravirine/ lamivudine/ tenof ovirdisoproxil .Hepatitis C antiviral agentselbasvir + grazoprevir(50 mg elbasvir QD +
200 mg grazoprevir QD,doravirine  100 mg QD) doravirine 
 AUC 1.56 (1.45, 1.68)Cmax 1.41 (1.25, 1.58)C24 
1.61 (1.45, 1.79)(Inhibition of  CYP3A)
  elbasvir 
 AUC 0.96 (0.90, 1.02)Cmax 
0.96 (0.91, 1.01)C24 
0.96 (0.89, 1.04)
  grazoprevir 
 AUC 1.07 (0.94, 1.23)Cmax 
1.22 (1.01, 1.47)C24 
0.90 (0.83, 0.96)No dose adjustment is required.12Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxilledipasvir + sof osbuvir(90 mg ledipasvir SD +
400 mg sof osbuvir SD,doravirine  100 mg SD)↑ doravirine 
 AUC 1.15 (1.07, 1.24)Cmax 
1.11 (0.97, 1.27)C24 
1.24 (1.13, 1.36)
  ledipasvir 
 AUC 0.92 (0.80, 1.06)Cmax 
0.91 (0.80, 1.02)
  sof osbuvir 
 AUC 1.04 (0.91, 1.18)Cmax 
0.89 (0.79, 1.00)
  GS-331007AUC 1.03 (0.98, 1.09)Cmax 
1.03 (0.97, 1.09)Expected: 
↑ tenofovir 
 Patients receivingdoravirine/ lamivudine/ tenof ovir disoproxil  concomitantly withledipasvir/sof osbuvirshould be monitored f or adversereactions associated with tenof ovirdisoproxil .sofosbuvir/velpatasvir 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil .Expected:
  doravirine
↑ tenofovir 
 Patients receivingdoravirine/ lamivudine/ tenof ovirdisoproxil  concomitantly withsofosbuvir/velpatasvir should bemonitored f or adverse reactionsassociated with tenof ovirdisoproxil.sof osbuvir 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
  doravirine 
 No dose adjustment is required.daclatasvir Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
  doravirine 
 No dose adjustment is required.ombitasvir/p aritaprevir/ritonavir  and dasabuvir +/
-ritonavir Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected :
 doravirine(Inhibition of  CYP3A due toritonavir)No dose adjustment is required.13Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxildasabuvir 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
  doravirine No dose adjustment is required
.glecaprevir, pibrentasvir
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected :
 doravirine (inhibition of  CYP3A)No dose adjustment is required
.ribavirin  Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
  doravirine 
 No dose adjustment is required
.Herbal supplements 
 St. John’s wort(Hypericum perforatum)Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
 doravirine(Induction of  CYP3A)Co-administration iscontraindicated.HIV antiviral agentstenof ovir disoproxil(300 mg QD,doravirine  100 mg SD)  doravirine 
 AUC 0.95 (0.80,
 1.12)Cmax 0.80 (0.64,  1.01)C24 
0.94 (0.78, 1.12)No dose adjustment is required.lamivudine 
+ tenof ovirdisoproxil(300 mg lamivudine SD +
245 mg tenof ovirdisoproxil SD,doravirine  100 mg SD)  doravirine 
 AUC 0.96 (0.87, 1.06)Cmax 
0.97 (0.88, 1.07)C24 
0.94 (0.83, 1.06)
lamivudine 
 AUC 0.94 (0.88, 1.00)Cmax 
0.92 (0.81, 1.05)
  tenof ovir 
 AUC 1.11 (0.97, 1.28)Cmax 
1.17 (0.96, 1.42)No dose adjustment is required.14Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxil 
 Immunosuppressantstacrolimussirolimus 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
  doravirine
↓ tacrolimus, sirolimus(Induction of  CYP3A)Monitor blood concentrations oftacrolimus and sirolimus as thedose of  these agents may need tobe adjusted .Kinase inhibitorsdabraf enib 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected: 
↓ doravirine(Induction of  CYP3A)Co-administration should beavoided. If  co
-administrationcannot be avoided, a 100
 mg doseof  doravirine should be takendaily, approximately
 12 h af ter thedose ofdoravirine/ lamivudine/ tenof ovirdisoproxil .Miscellaneoussorbitol solution (3.2
 g,
10.2 g, 13.4  g)/lamivudine 
 Single dose lamivudine oral solution
300 mglamivudine 
 AUC  14 %; 32  %; 35  %Cmax  28 %; 52  %; 55  %When possible, avoid chronic co
-administration ofdoravirine/lamivudine/tenof ovirdisoproxil with medicinalproducts containing sorbitol orother osmotic acting poly
-alcohols(e.g., xylitol, mannitol, lactitol,maltitol). Consider more frequentmonitoring of  HIV
-
1 viral loadwhen chronic co
-administrationcannot be avoided.15Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxil 
 Opioid analgesicsmethadone(20-200 mg QDindividuali sed dose,doravirine  100 mg QD) doravirine 
 AUC 0.74 (0.61, 0.90)Cmax 
0.76 (0.63, 0.91)C24 
0.80 (0.63, 1.03)
  R-methadone 
 AUC 0.95 (0.90, 1.01)Cmax 
0.98 (0.93, 1.03)C24 
0.95 (0.88, 1.03)
  S-methadone  AUC 0.98 (0.90, 1.06)Cmax 
0.97 (0.91, 1.04)C24 
0.97 (0.86, 1.10)No dose adjustment is required.buprenorphinenaloxone 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
  buprenorphine
  naloxone 
 No dose adjustment is required.Oral contraceptives
0.03 mg ethinyl oestradiol /
0.15 mg levonorgestrel SD, doravirine  100 mg QD  ethinyl oestradiol 
 AUC 0.98 (0.94, 1.03)Cmax 
0.83 (0.80, 0.87)
 levonorgestrel 
 AUC 1.21 (1.14, 1.28)Cmax 
0.96 (0.88, 1.05)No dose adjustment is required.norgestimate/ethinyloestradiol 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil .Expected:
  norgestimate/ethinyl oestradiol 
 No dose adjustment is required.Psychostimulantsmodaf inil 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected: 
↓ doravirine(Induction of  CYP3A)Co-administration should beavoided. If  co -administrationcannot be avoided, a 100
 mg doseof  doravirine should be takendaily, approximately
12 h af ter thedose ofdoravirine/ lamivudine/ tenof ovirdisoproxil .Sedatives/Hypnoticsmidazolam(2 mg SD,doravirine  120 mg QD) midazolam 
 AUC 0.82 (0.70, 0.97)Cmax 
1.02 (0.81, 1.28)No dose adjustment is required.16Medicinal product bytherapeutic area 
 Effects on medicinal product levelsgeometric mean ratio (90  % CI)*Recommendation concerningco-administration withdoravirine/ lamivudine/tenofovirdisoproxil 
 Statinsatorvastatin(20 mg SD,doravirine 100
 mg QD)  atorvastatin 
 AUC 0.98 (0.90, 1.06)Cmax 
0.67 (0.52, 0.85)No dose adjustment is required.rosuvastatinsimvastatin 
 Interaction not studied withdoravirine ordoravirine/ lamivudine/ tenof ovirdisoproxil.Expected:
  rosuvastatin
  simvastatin 
 No dose adjustment is required.
 = increase, ↓ = decrease, ↔   = no change 
 CI = Conf idence Interval; SD = Single Dose; QD = Once Daily; BID = Twice Daily
*AUC 0- f or single  dose, AUC 0-24 f or once daily.
